Copenhagen, 2013-09-16 10:14 CEST (GLOBE NEWSWIRE) --
| Report of insider transactions No. 04/2013 |
Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them.
In this regard, Zealand announces the following transaction:
| Name: | David H. Solomon |
| Reason: | President and Chief Executive Officer |
| Issuer: | Zealand Pharma A/S |
| Type | Shares |
| ISIN code: | DK0060257814 |
| Transactio n: | Purchase |
| Trading date: | 12 September 2013 |
| Market: | NASDAQ OMX København A/S |
| Amount: | 10,000 |
| Price: | DKK 64.00 |
| Market value: | DKK 640,000.00 |
Hereafter, David H. Solomon owns 30,600 shares and 387,150 warrants in Zealand.
***
For further information, please contact:
David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300
Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand PharmaZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia ® ) is approved in Europe and Japan and under regulatory review in a number of other countries globally. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA CV outcome study.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com .
@ZealandPharma